Fermenta Biotech [FERMENTA] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
Fermenta Biotech
BSE
Loading...
Sun Pharmaceutical
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Fermenta Biotech wins in 10 metrics, Sun Pharmaceutical wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Fermenta Biotech | Sun Pharmaceutical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 9.13 | 37.73 | Fermenta Biotech |
| Price-to-Book Ratio | 2.66 | 5.42 | Fermenta Biotech |
| Debt-to-Equity Ratio | 32.06 | 3.26 | Sun Pharmaceutical |
| PEG Ratio | -0.02 | -1.94 | Sun Pharmaceutical |
| EV/EBITDA | 7.12 | 23.98 | Fermenta Biotech |
| Profit Margin (TTM) | 19.81% | 19.29% | Fermenta Biotech |
| Operating Margin (TTM) | 16.45% | 24.34% | Sun Pharmaceutical |
| EBITDA Margin (TTM) | 16.45% | 24.34% | Sun Pharmaceutical |
| Return on Equity | 21.44% | 15.08% | Fermenta Biotech |
| Return on Assets (TTM) | 12.51% | 11.87% | Fermenta Biotech |
| Free Cash Flow (TTM) | $187.69M | $119.44B | Sun Pharmaceutical |
| Dividend Yield | 0.71% | 1.26% | Sun Pharmaceutical |
| 1-Year Return | 2.71% | -13.00% | Fermenta Biotech |
| Price-to-Sales Ratio (TTM) | 1.81 | 7.28 | Fermenta Biotech |
| Enterprise Value | $10.03B | $3,678.87B | Sun Pharmaceutical |
| EV/Revenue Ratio | 1.90 | 6.84 | Fermenta Biotech |
| Gross Profit Margin (TTM) | 65.48% | 79.58% | Sun Pharmaceutical |
| Revenue per Share (TTM) | $181 | $224 | Sun Pharmaceutical |
| Earnings per Share (Diluted) | $35.83 | $43.23 | Sun Pharmaceutical |
| Beta (Stock Volatility) | -0.16 | 0.28 | Fermenta Biotech |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Fermenta Biotech vs Sun Pharmaceutical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Fermenta Biotech | -4.24% | 0.34% | -8.40% | -1.87% | 23.06% | -17.75% |
| Sun Pharmaceutical | -0.10% | 4.12% | 4.66% | -1.50% | -0.70% | -12.45% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Fermenta Biotech | 2.71% | 61.94% | -8.27% | 70.06% | 70.06% | 70.06% |
| Sun Pharmaceutical | -13.00% | 69.49% | 239.84% | 85.82% | 711.29% | 2,598.03% |
News Based Sentiment: Fermenta Biotech vs Sun Pharmaceutical
Fermenta Biotech
News based Sentiment: POSITIVE
Fermenta Biotech’s Q3 FY24 results demonstrate significant revenue and profit growth, driven by its Vitamin D3 business. The company’s commitment to sustainability further enhances its long-term investment appeal, making this a noteworthy month for investors.
Sun Pharmaceutical
News based Sentiment: MIXED
October was a month of significant contrasts for Sun Pharma. While the company demonstrated revenue growth and made strategic acquisitions, the imposition of a 100% US tariff on Indian pharmaceuticals presents a major headwind. This combination of positive and negative developments creates a mixed investment outlook.
Performance & Financial Health Analysis: Fermenta Biotech vs Sun Pharmaceutical
| Metric | FERMENTA | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹9.82B | ₹4.01T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 24,185 | 3,168,435 |
| 90 Day Avg. Volume | 29,849 | 2,778,768 |
| Last Close | ₹308.45 | ₹1,653.10 |
| 52 Week Range | ₹219.00 - ₹449.00 | ₹1,548.00 - ₹1,947.00 |
| % from 52W High | -31.30% | -15.10% |
| All-Time High | ₹449.00 (Feb 10, 2025) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -31.30% | -15.67% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.74% | 0.10% |
| Quarterly Earnings Growth | 0.74% | -0.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.20% | 0.19% |
| Operating Margin (TTM) | 0.16% | 0.24% |
| Return on Equity (TTM) | 0.21% | 0.15% |
| Debt to Equity (MRQ) | 32.06 | 3.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹123.23 | ₹300.99 |
| Cash per Share (MRQ) | ₹24.01 | ₹108.88 |
| Operating Cash Flow (TTM) | ₹-59,490,000 | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹768.62M | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.71% | 1.26% |
| Last 12-Month Dividend | ₹2.50 | ₹21.00 |
Valuation & Enterprise Metrics Analysis: Fermenta Biotech vs Sun Pharmaceutical
| Metric | FERMENTA | SUNPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 9.13 | 37.73 |
| Forward P/E | N/A | 49.91 |
| PEG Ratio | -0.02 | -1.94 |
| Price to Sales (TTM) | 1.81 | 7.28 |
| Price to Book (MRQ) | 2.66 | 5.42 |
| Market Capitalization | ||
| Market Capitalization | ₹9.82B | ₹4.01T |
| Enterprise Value | ₹10.03B | ₹3.68T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.90 | 6.84 |
| Enterprise to EBITDA | 7.12 | 23.98 |
| Risk & Other Metrics | ||
| Beta | -0.16 | 0.28 |
| Book Value per Share (MRQ) | ₹123.23 | ₹300.99 |
Financial Statements Comparison: Fermenta Biotech vs Sun Pharmaceutical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | FERMENTA | SUNPHARMA |
|---|---|---|
| Revenue/Sales | ₹1.36B | ₹137.86B |
| Cost of Goods Sold | ₹470.43M | ₹28.15B |
| Gross Profit | ₹892.20M | ₹109.71B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹224.21M | ₹33.72B |
| EBITDA | ₹370.04M | ₹47.66B |
| Pre-Tax Income | ₹280.87M | ₹31.73B |
| Income Tax | ₹64.85M | ₹8.70B |
| Net Income (Profit) | ₹216.02M | ₹22.93B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | FERMENTA | SUNPHARMA |
|---|---|---|
| Cash & Equivalents | ₹282.40M | ₹102.69B |
| Total Current Assets | ₹3.35B | ₹526.24B |
| Total Current Liabilities | ₹2.12B | ₹181.94B |
| Long-Term Debt | ₹194.91M | ₹3.58B |
| Total Shareholders Equity | ₹3.59B | ₹724.86B |
| Retained Earnings | ₹3.25B | ₹578.62B |
| Property, Plant & Equipment | ₹2.16B | ₹100.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | FERMENTA | SUNPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | FERMENTA | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 24,185 | 3,168,435 |
| Average Daily Volume (90 Day) | 29,849 | 2,778,768 |
| Shares Outstanding | 29.17M | 2.40B |
| Float Shares | 8.54M | 1.06B |
| % Held by Insiders | 0.70% | 0.56% |
| % Held by Institutions | 0.00% | 0.25% |
Dividend Analysis & Yield Comparison: Fermenta Biotech vs Sun Pharmaceutical
| Metric | FERMENTA | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹2.50 | ₹21.00 |
| Last 12-Month Dividend Yield | 0.71% | 1.26% |
| 3-Year Avg Annual Dividend | ₹0.83 | ₹14.67 |
| 3-Year Avg Dividend Yield | 0.71% | 0.46% |
| 3-Year Total Dividends | ₹2.50 | ₹44.00 |
| Ex-Dividend Date | Aug 06, 2025 | Jul 07, 2025 |